The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.

, , , ,,
Department of Immunology

van Luijn, M., van den Ancker, W., van Ham, M., & van de Loosdrecht, A. (2014). Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia. OncoImmunology, 3(12), 1–3. doi:10.4161/21624011.2014.941737